Pauline Castelnau-Marchand1, Antonin Levy1,2,3, Antoine Moya-Plana4, Haïtham Mirghani4, France Nguyen1, Eleonor Rivin Del Campo1, François Janot4, Frédéric Kolb4, François-Régis Ferrand4, Stéphane Temam4, Pierre Blanchard1, Yungan Tao5. 1. Department of Radiation Oncology, Gustave-Roussy, Université Paris-Saclay, , F-94805, 114 Rue Edouard Vaillant, 94800, Villejuif, France. 2. INSERM U1030, Molecular Radiotherapy, Gustave-Roussy, Université Paris-Saclay, F-94805, 94800, Villejuif, France. 3. Univ Paris Sud, Université Paris-Saclay, F-94270, Le Kremlin-Bicêtre, France. 4. Department of Head and Neck Oncology, Gustave-Roussy, Université Paris-Saclay, F-94805, 114 Rue Edouard Vaillant, 94800, Villejuif, France. 5. Department of Radiation Oncology, Gustave-Roussy, Université Paris-Saclay, , F-94805, 114 Rue Edouard Vaillant, 94800, Villejuif, France. yungan.tao@gustaveroussy.fr.
Abstract
OBJECTIVES: The purpose of this work was to report outcomes of patients with nonmetastatic sinonasal squamous cell carcinoma (SNSCC) and to discuss the impact of elective neck irradiation (ENI) and selective neck dissection (SND) in clinically negative lymph node (N0) patients. METHODS: Data from 104 nonmetastatic SNSCC patients treated with curative intent were retrospectively analysed. Uni- and multivariate analyses were used to assess prognostic factors of overall survival (OS) and locoregional control (LRC). RESULTS: Median follow-up was 4.5 years. Eighty-five percent of tumours were stage III-IV. Treatments included induction chemotherapy (52.9 %), surgery (72 %) and radiotherapy (RT; 87 %). The 5‑year OS, progression-free survival, and LRC rates were 48, 44 and 57 %, respectively. Absence of surgery predicted a decrease of OS (hazard ratio [HR] 2.6; 95 % confidence interval [CI] 1.4-4.7), and LRC (HR 3.5; 95 % CI 1.8-6.8). Regional relapse was observed in 13/104 (13 %) patients and most common sites were level II (n = 12; 70.6 %), level III (n = 5; 29.4 %) and level Ib (n = 4; 23.5 %). Management of the neck in N0 patients (n = 87) included 11 % SND alone, 32 % ENI alone, 20 % SND + ENI and 37 % no neck treatment. In this population, a better LRC was found according to the management of the neck in favour of SND (94 % vs. 47 %; p = 0.002) but not ENI. CONCLUSION: SND may detect occult cervical positive nodes, allowing selective postoperative RT. ENI (ipsilateral level II, ±Ib and III or bilateral) needs to be proposed in selected patients, especially when SND has not been performed.
OBJECTIVES: The purpose of this work was to report outcomes of patients with nonmetastatic sinonasal squamous cell carcinoma (SNSCC) and to discuss the impact of elective neck irradiation (ENI) and selective neck dissection (SND) in clinically negative lymph node (N0) patients. METHODS: Data from 104 nonmetastatic SNSCC patients treated with curative intent were retrospectively analysed. Uni- and multivariate analyses were used to assess prognostic factors of overall survival (OS) and locoregional control (LRC). RESULTS: Median follow-up was 4.5 years. Eighty-five percent of tumours were stage III-IV. Treatments included induction chemotherapy (52.9 %), surgery (72 %) and radiotherapy (RT; 87 %). The 5‑year OS, progression-free survival, and LRC rates were 48, 44 and 57 %, respectively. Absence of surgery predicted a decrease of OS (hazard ratio [HR] 2.6; 95 % confidence interval [CI] 1.4-4.7), and LRC (HR 3.5; 95 % CI 1.8-6.8). Regional relapse was observed in 13/104 (13 %) patients and most common sites were level II (n = 12; 70.6 %), level III (n = 5; 29.4 %) and level Ib (n = 4; 23.5 %). Management of the neck in N0 patients (n = 87) included 11 % SND alone, 32 % ENI alone, 20 % SND + ENI and 37 % no neck treatment. In this population, a better LRC was found according to the management of the neck in favour of SND (94 % vs. 47 %; p = 0.002) but not ENI. CONCLUSION: SND may detect occult cervical positive nodes, allowing selective postoperative RT. ENI (ipsilateral level II, ±Ib and III or bilateral) needs to be proposed in selected patients, especially when SND has not been performed.
Authors: B Jeremic; Y Shibamoto; B Milicic; N Nikolic; A Dagovic; J Aleksandrovic; Z Vaskovic; L Tadic Journal: Cancer Date: 2000-05-15 Impact factor: 6.860
Authors: A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: Bradford S Hoppe; Lauren D Stegman; Michael J Zelefsky; Kenneth E Rosenzweig; Suzanne L Wolden; Snehal G Patel; Jatin P Shah; Dennis H Kraus; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-08 Impact factor: 7.038
Authors: Danny R Youlden; Susanna M Cramb; Susan Peters; Sandro V Porceddu; Henrik Møller; Lin Fritschi; Peter D Baade Journal: Cancer Epidemiol Date: 2013-10-16 Impact factor: 2.984
Authors: Robert P Takes; Alfio Ferlito; Carl E Silver; Alessandra Rinaldo; Jesus E Medina; K Thomas Robbins; Juan P Rodrigo; Marc Hamoir; Carlos Suárez; Peter Zbären; Vanni Mondin; Ashok R Shaha; William M Mendenhall; Primož Strojan Journal: Eur Arch Otorhinolaryngol Date: 2013-06-20 Impact factor: 2.503